Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
Abstract
To determine the accuracy with which Medicare claims data measure disease-free survival
in elderly Medicare beneficiaries with cancer, we performed a criterion validation
study. We merged gold-standard clinical trial data of 45 elderly patients with node-positive
breast cancer who were treated on the Cancer and Leukemia Group B (CALGB) adjuvant
breast trial 9344 with Centers for Medicare and Medicaid Services (CMS) data files
and compared the results of a CMS-based algorithm with the CALGB disease-free survival
information to determine sensitivity and specificity. For 5-year disease-free survival,
the sensitivity of the CMS-based algorithm was 100% (95% confidence interval [CI]
= 81% to 100%), the specificity was 97% (95% CI = 83% to 100%), and the area under
the receiver operator curve was 98[corrected]% (95% CI = 95[corrected]% to 100%).
For 2-year disease-free survival, the test characteristics were less favorable: sensitivity
was 83% (95% CI = 36% to 100%), specificity was 95% (95% CI = 83% to 100%), and area
under the receiver operator curve was 89[corrected]% (95% CI = 72[corrected]% to 100%).
Type
Journal articleSubject
AgedAlgorithms
Area Under Curve
Breast Neoplasms
Disease-Free Survival
Female
Humans
Lymphatic Metastasis
Medicaid
Medicare
Middle Aged
Multicenter Studies as Topic
Neoplasm Recurrence, Local
ROC Curve
Sensitivity and Specificity
United States
Permalink
https://hdl.handle.net/10161/16103Published Version (Please cite this version)
10.1093/jnci/djj363Publication Info
Lamont, Elizabeth B; Herndon, James E; Weeks, Jane C; Henderson, I Craig; Earle, Craig
C; Schilsky, Richard L; ... Cancer and Leukemia Group B (2006). Measuring disease-free survival and cancer relapse using Medicare claims from CALGB
breast cancer trial participants (companion to 9344). J Natl Cancer Inst, 98(18). pp. 1335-1338. 10.1093/jnci/djj363. Retrieved from https://hdl.handle.net/10161/16103.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
James Emmett Herndon II
Professor of Biostatistics & Bioinformatics
Current research interests have application to the design and analysis of cancer clinical
trials. Specifically, interests include the use of time-dependent covariables within
survival models, the design of phase II cancer clinical trials which minimize some
of the logistical problems associated with their conduct, and the analysis of longitudinal
studies with informative censoring (in particular, quality of life studies of patients
with advanced cancer).

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info